SRNE - Sorrento Therapeutics, Inc.
| Previous Close | 4.45 |
| Open | 4.40 |
| Bid | 4.05 x 1000 |
| Ask | 4.60 x 1000 |
| Day's Range | 4.05 - 4.50 |
| 52 Week Range | 1.67 - 10.65 |
| Volume | 2,005,701 |
| Avg. Volume | 1,712,187 |
| Market Cap | 467.294M |
| Beta | 3.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.70 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.67 |
- CNBC Videos•5 months ago
Cramer's lightning round: Take a long-term view on Spotif...
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a newly public streaming play.
- GlobeNewswire•4 days ago
Scilex Announces Pricing and Availability of ZTlido™ for the Commercial Launch of its First Product in October of 2018
Scilex Pharmaceuticals Inc. (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (SRNE) (Sorrento), today announced that the Wholesale Acquisition Cost (WAC) for ZTlido™ (lidocaine topical system) 1.8% (ZTLIDO) is $8.98 per patch and is now listed in pricing compendia. Post-herpetic neuralgia (PHN), also referred to as post-shingles pain, is a frequent complication of shingles, a condition caused by the herpes zoster (HZ) virus, which afflicts an estimated 1 million people each year in the US.
- GlobeNewswire•13 days ago
Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing to Support the Commercialization of Non-Opioid ZTlido™ Pain Medication
Sorrento Therapeutics, Inc. (SRNE) (“Sorrento”) announced today that its majority-owned subsidiary, Scilex Pharmaceuticals Inc. (“Scilex”), closed a debt financing with leading global institutional investors for aggregate gross proceeds to Scilex of $140 million. Scilex intends to use the net proceeds from this transaction for working capital and general corporate purposes in respect of commercialization of ZTlido™ (lidocaine topical system) 1.8%. Morgan Stanley & Co. LLC acted as sole structuring agent for the transaction. “This non-dilutive financing provides Scilex with the capital resources to successfully execute on the launch of ZTlido,” said Henry Ji, Chairman, President and Chief Executive Officer of Sorrento and Scilex.
- PR Newswire•15 days ago
Scilex Presents ZTlido™ Data on Superior Adhesion over Lidocaine Patch Formulation
- Data Presented at PAINWeek® Also Showed ZTlido Was Well-Tolerated and Demonstrated Bioequivalence to Lidoderm® Patch1,2 - Study Results Make Strong Case for ZTlido as Non-Opioid Treatment for Post-Shingles ...
- GlobeNewswire•19 days ago
Research Report Identifies Brady, Akari Therapeutics, MTGE Investment, Jones Lang LaSalle, New Relic, and Sorrento Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Sept. 04, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•20 days ago
Sorrento Therapeutics to Present at FB Riley and HC Wainwright Sept 2018 Healthcare Conferences in NYC (NY)
SAN DIEGO, Sept. 02, 2018-- Sorrento Therapeutics, Inc., announced today that Dr. Henry Ji, Chairman and CEO, will be participating in upcoming investment healthcare conferences.. FB Riley Healthcare Conference ...
- Benzinga•last month
Sorrento's Knee Pain Medication Found Safe, Effective Based On Early Data
Sorrento Therapeutics Inc (NASDAQ: SRNE ) shares were rallying Monday following the announcement of positive trial results for its osteoarthritis knee pain treatment candidate. In pre-market trading, the ...
- GlobeNewswire•last month
1st Patient Treated for Osteoarthritis Knee Pain in Sorrento Resiniferatoxin Phase 1B Trial Meets Both Safety and Efficacy Expectations
Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that the first enrolled patient in the phase 1b study of its non-opioid, afferent nerve ablating drug candidate (resiniferatoxin or “RTX”) for the treatment of pain from osteoarthritis in the knee (intra-articular route of administration) received treatment on July 31, 2018. In a planned safety assessment, the data monitoring committee (DMC) found no safety concerns, and the study will continue as planned. “Joint pain affects over 30 million patients in major markets, half of which suffer from knee osteoarthritis pain1. A clear unmet need for a single administration long-lasting non-opioid and non-steroidal pain control solution exists for this degenerative joint disease” stated Dr. Jerome Zeldis, Chief Medical Officer for Sorrento.
- ACCESSWIRE•2 months ago
Today’s Research Reports on Stocks to Watch: Ampio Pharmaceuticals and Sorrento Therapeutics
NEW YORK, NY / ACCESSWIRE / July 23, 2018 / Ampio Pharmaceuticals and Sorrento Therapeutics both saw big moves in opposite directions on Friday. Ampio Pharmaceuticals, Inc. shares closed up 11.44% on Friday with trading volume roughly three times higher than usual at 2,251,564 shares traded. It was recently revealed that Susquehanna International Group Llp has increased its position in the stock by $57,249.
- ACCESSWIRE•2 months ago
Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks
LONDON, UK / ACCESSWIRE / July 23, 2018/ If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.
- Motley Fool•3 months ago
Why Clean Energy Fuels, Sorrento Therapeutics, and iQiyi Slumped Today
From an analyst downgrade to new tariffs on China, see why these three companies fell on Thursday.
- Motley Fool•3 months ago
Why Sorrento Therapeutics, Inc. Stock Sank Today
The biotech's share price dropped on no news -- but perhaps plenty of worries.
- GlobeNewswire•3 months ago
Sorrento Acquires the Sofusa™ Lymphatic Delivery Platform for Immune-Oncology (I-O) Antibody Therapeutics
SAN DIEGO, July 03, 2018-- Sorrento Therapeutics, Inc. announced today that it acquired the Sofusa™ lymphatic delivery technology platform from Kimberly-Clark Corporation for targeted biopharmaceuticals, ...
- ACCESSWIRE•3 months ago
Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks
LONDON, UK / ACCESSWIRE / June 26, 2018/ If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Monday, June 25, 2018, US markets saw broad based losses with seven out of nine sectors finishing the trading sessions in red.
Reuters•3 months agoHong Kong market could open cash flood gates for U.S. biotechs
Sorrento Therapeutics Inc is among a few early-stage U.S. biotechs wary of being overlooked in a crowded New York stock market and looking at listing itself in Hong Kong as Asia's financial center rolls out the red carpet with a drastic overhaul of listing rules. Striving to catch up with New York and Shanghai as an IPO hotspot, the Hong Kong Stock Exchange announced new policies late last year that actively court biotech companies, including those that do not have a drug on the market.
- Reuters•3 months ago
Hong Kong market could open cash flood gates for U.S. biotechs
When U.S. biotech startup Sorrento Therapeutics named ex-Lehman Brothers executive Jiong Shao as its new finance chief about two months ago, it was widely seen as a move driven by his background in raising capital for Alibaba and Tencent. Sorrento Therapeutics Inc is among a few early-stage U.S. biotechs wary of being overlooked in a crowded New York stock market and looking at listing itself in Hong Kong as Asia's financial center rolls out the red carpet with a drastic overhaul of listing rules.
- ACCESSWIRE•4 months ago
Free Research Reports on Sorrento Therapeutics and Three More Biotech Stocks
LONDON, UK / ACCESSWIRE / May 25, 2018 / If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Thursday, May 24, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Sierra Oncology Inc. (NASDAQ: SRRA), Sorrento Therapeutics Inc. (NASDAQ: SRNE), Spark Therapeutics Inc. (NASDAQ: ONCE), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI).
- Simply Wall St.•4 months ago
An Intrinsic Calculation For Sorrento Therapeutics Inc (NASDAQ:SRNE) Shows It’s 26% Undervalued
I am going to run you through how I calculated the intrinsic value of Sorrento Therapeutics Inc (NASDAQ:SRNE) using the discounted cash flow (DCF) method. If you want to learnRead More...
- ACCESSWIRE•5 months ago
Today's Research Reports on Trending Tickers: Sorrento Therapeutics and Illumina
Investor attention will now shift to President Trump's decision on the Iran nuclear accord on Tuesday at 2:00 p.m. The Dow Jones Industrial Average gained 0.39 percent to close at 24,357.32, while the S&P 500 Index rose 0.35 percent to close at 2,672.63. The Nasdaq Composite Index jumped 0.77 percent to close at 7,265.21. If Trump pulls out, which other leaders have urged him not to do, then supply will be cut, which will have the same impact as rising demand in terms of driving up prices.
- PR Newswire•5 months ago
Lifshitz & Miller LLP Announces Investigation of Cancer Genetics, Inc., Colony Northstar, Inc., Pacific Commerce Bancorp, MiMedx Group, Inc., Sorrento Therapeutics, Inc., TrueCar, Inc., and Windstream Holdings, Inc.
NEW YORK , April 24, 2018 /PRNewswire/ -- Cancer Genetics, Inc. (CGIX) Lifshitz & Miller announces investigation into possible securities law violations in connection with Cancer Genetics' announcement ...
- CNBC•5 months ago
Cramer's lightning round: Take a long-term view on Spotify
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a newly public streaming play.
